These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126 [TBL] [Abstract][Full Text] [Related]
27. Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. Brardi S; Cevenini G; Verdacchi T; Romano G; Ponchietti R Arch Ital Urol Androl; 2015 Mar; 87(1):66-71. PubMed ID: 25847900 [TBL] [Abstract][Full Text] [Related]
28. Use of cinacalcet HCl to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism. Bahner U; Brandl M; Nies C; Schmidt-Gayk H J Ren Nutr; 2008 Jul; 18(4):383-8. PubMed ID: 18558304 [TBL] [Abstract][Full Text] [Related]
29. Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia. Alon US; VandeVoorde RG Pediatr Nephrol; 2010 Sep; 25(9):1747-50. PubMed ID: 20495831 [TBL] [Abstract][Full Text] [Related]
30. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Fukagawa M; Yumita S; Akizawa T; Uchida E; Tsukamoto Y; Iwasaki M; Koshikawa S; Nephrol Dial Transplant; 2008 Jan; 23(1):328-35. PubMed ID: 17717030 [TBL] [Abstract][Full Text] [Related]
31. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Serra AL; Savoca R; Huber AR; Hepp U; Delsignore A; Hersberger M; Wüthrich RP Nephrol Dial Transplant; 2007 Feb; 22(2):577-83. PubMed ID: 17005527 [TBL] [Abstract][Full Text] [Related]
32. Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism. Timmons JG; Manners R; Bailey M; McDougall C Hormones (Athens); 2021 Sep; 20(3):587-589. PubMed ID: 33881757 [TBL] [Abstract][Full Text] [Related]
33. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487 [TBL] [Abstract][Full Text] [Related]
34. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Szwarc I; Argilés A; Garrigue V; Delmas S; Chong G; Deleuze S; Mourad G Transplantation; 2006 Sep; 82(5):675-80. PubMed ID: 16969292 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic failure of cinacalcet in a renal transplant patient presenting hyperparathyroidism with severe hypercalcaemia. Boulanger H; Haymann JP; Fouqueray B; Mansouri R; Metivier F; Sarfati E; Glotz D Nephrol Dial Transplant; 2005 Dec; 20(12):2865. PubMed ID: 16115841 [No Abstract] [Full Text] [Related]
36. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294 [TBL] [Abstract][Full Text] [Related]
37. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. Torres PU J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031 [TBL] [Abstract][Full Text] [Related]
38. Parathyroid gland: cinacalcet-can it control hypercalcemia? de Francisco AL; Piñera C Nat Rev Endocrinol; 2010 Jan; 6(1):15-7. PubMed ID: 20010966 [No Abstract] [Full Text] [Related]